China Biologic Products, one of the leading plasma-based biopharmaceutical companies, has announced that its wholly-owned subsidiary, Logic Management Consulting has agreed to acquire the remaining 10 percent ownership in Guiyang Dalin Biologic Technologies, a limited liability company. Logic China already owns a 90 percent majority interest in Dalin. Upon consummation of the acquisition, Dalin will become a wholly-owned subsidiary of Logic China. Dalin is the largest shareholder of Qianfeng Biological Products, one of the largest plasma-based biopharmaceutical companies in China. Mr. Shaowen Fan, owner of Dalin has agreed on purchase price of approximately $7,530,120 from Logic China. China Biologic, through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies and its equity investment in Xi'an Huitian Blood Products is currently one of the leading plasma-based biopharmaceutical companies in China. The company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The company sells its products to hospitals and other healthcare facilities in China.